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Obesity is a major health problem, and although caloric restriction and exercise are successful strategies 
to lose adipose tissue in obese individuals, a simultaneous decrease in skeletal muscle mass, negatively 
effects metabolism and muscle function. To deeper understand molecular events occurring in muscle 
during weight-loss, we measured the expressional change in human skeletal muscle following a 
combination of severe caloric restriction and exercise over 4 days in 15 Swedish men. Key metabolic 
genes were regulated after the intervention, indicating a shift from carbohydrate to fat metabolism. 
Nicotinamide N-methyltransferase (NNMT) was the most consistently upregulated gene following 
the energy-deficit exercise. Circulating levels of N1-methylnicotinamide (MNA), the product of NNMT 
activity, were doubled after the intervention. The fasting-fed state was an important determinant of 
plasma MNA levels, peaking at ~18 h of fasting and being lowest ~3 h after a meal. In culture, MNA was 
secreted by isolated human myotubes and stimulated lipolysis directly, with no effect on glucagon 
or insulin secretion. We propose that MNA is a novel myokine that enhances the utilization of energy 
stores in response to low muscle energy availability. Future research should focus on applying MNA as a 
biomarker to identify individuals with metabolic disturbances at an early stage.
The number of individuals who are overweight or obese is increasing worldwide and obesity elevates the risk 
of many serious diseases, including certain forms of cancer, cardiovascular disease and type 2 diabetes (T2D). 
Failure to address a continued increase in obesity will thus have negative effects on life expectancy1. The total 
estimated cost of diabetes diagnosed in the U.S. in 2012 was $245 billion, which is an increase by more than 40% 
in 5 years2. However, obesity can be counteracted by reducing energy intake and increasing energy expenditure 
thereby achieving a negative energy balance. Several studies support the use of exercise in combination with die-
tary changes as a weight-loss strategy3–5. An important reason to include exercise in a weight-loss program is its 
effect on preserving fat-free mass (FFM)4,6, which is essential when combating obesity6. Skeletal muscle produces 
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myokines which e.g. can regulate mitochondrial efficiency and thereby contribute to decreasing fat mass and insu-
lin resistance7. Many weight-loss programs successfully achieve short-term weight loss, but the major challenge is 
that overweight/obese individuals fail to sustain the weight reduction over time8,9.
Most successful strategies rely on lifestyle interventions ranging from several weeks to months. However, we 
have recently shown that a clinically relevant reduction in fat mass can be achieved and maintained in overweight 
men by an intense 4-day intervention, combining prolonged low-intensity exercise (9 h/day) and severe caloric 
restriction10. Following the 4-day intervention, total body mass was reduced by 4.9 kg, of which ~40% (2.1 kg) was 
fat mass. More importantly, the reduction in body mass was sustained (4.4 kg) four weeks after the intervention 
and the relative reduction in fat mass was increased to 90% (3.8 kg) of the total decrease in body mass. The major-
ity of this reduction (~70%) was accounted for by loss of trunk fat, leading to a diminished waist circumference 
(~7 cm). A significant reduction in body weight (2.4 kg) was maintained a year after the intervention, most of 
which (~80%) was due to loss of fat mass. This weight reduction was accompanied by improvements in blood 
lipids, e.g. reduced total cholesterol and low-density lipoprotein levels.
Although loss of adipose tissue is beneficial, a simultaneous decrease in skeletal muscle mass has negative 
effects on metabolism as well as muscle function and performance11,12. In order to minimize such negative effects 
of exercise during an energy deficit state, a deeper understanding on a detailed molecular level is needed. Thus, 
the aim of the present study was to examine changes in gene expression in skeletal muscle in response to exercise 
combined with severe energy deficit.
Results
Changes in skeletal muscle mRNA expression in response to severe energy deficit. Fifteen over-
weight Swedish men were exposed to a combination of caloric restriction and high-volume-low-intensity exercise 
for 4 days yielding a ~ 5000 kcal/day negative energy balance and an average total decrease in fat mass of 2.1 kg10. 
During the intervention, one arm was exercised each morning for 45 minutes followed by ~ 8 h of hiking. After the 
intervention, the participants were again examined after 3 days of isoenergetic diet and reduced exercise (maxi-
mum 10000 steps/day). Skeletal muscle biopsies were taken (3 at each time point) in the fasted state in the morn-
ing at 3 time points during the study from both the exercised and non-exercised arm muscles (deltoid) and from 
one leg muscle (vastus lateralis), i.e. before (PRE) and after (WCR, i.e. Walking + Caloric Restriction) the 4-day 
intervention and after the reexamination 3 days later (DIET). Characteristics of the participants are presented in 
Supplementary Table S1. To study changes in muscle gene expression in response to low energy availability, we 
performed a microarray analysis using the Illumina Beadarray system. During the WCR period the diet consisted 
of 0.8 g/kg body mass of whey protein (n = 8) or sucrose (n = 7), split into three doses (morning, midday and 
afternoon). There was no significant difference in muscle gene expression due to diet (whey protein or sucrose), 
i.e. no genes were observed with a significant change in expression between the two diets in response to the inter-
vention (padj > 0.05), therefore the two diet groups were merged for subsequent analyses (n = 15). In the non-ex-
ercised arm, 39 genes were differentially expressed between PRE and WCR (false discovery rate (FDR) < 5%), 
14 showed higher and 25 lower expression at WCR. In the exercised arm, 44 genes were differentially expressed 
(FDR < 5%), 22 genes showed higher and 22 lower expression (WCR vs. PRE, FDR < 5%). In the leg, 421 genes 
were differentially expressed (FDR < 5%), 207 increased and 214 decreased (WCR vs. PRE)—(Supplementary 
Table S2). This larger number of differentially expressed genes in the leg could reflect the higher amount of work 
performed by this muscle group during the intervention. The 10 most differentially expressed genes (increased 
and decreased) at WCR compared with PRE in the exercised, non-exercised arm and leg muscles are reported 
in Table 1. Genes differentially expressed in more than one tissue are presented in Supplementary Fig. S1, e.g. 
19 genes were found in all three muscle tissues. The most consistent decreased expression was observed for the 
transferrin receptor (TFRC) gene (0.17, 0.15 and 0.19; padj < 0.001) for non-exercised, exercised arm and leg mus-
cles respectively (WCR vs. PRE). In contrast, Nicotinamide N-methyltransferase (NNMT) was upregulated 5.4, 
4.2 and 2.9-fold at WCR compared with PRE (padj < 0.05) in non-exercised and exercised arm and leg muscles, 
respectively.
The only gene found to be differentially expressed between DIET and WCR (FDR < 5%) in the non-exercised 
arm was carnitine palmitoyltransferase 2 (CPT2). In the exercised arm, three genes, SCHIP1, CPT2 and 
high-mobility group protein B2 (HMGB2), were differentially expressed (DIET vs. WCR, FDR < 5%). Of these, 
HMGB2 and CPT2 were regulated in the opposite direction, i.e. increased expression after the 4-day intervention 
and reduced after the 3-day follow up. In the leg, 147 genes were found differentially expressed between DIET and 
WCR (FDR < 5%). Out of these, 121 (82%) were regulated in the opposite direction in WCR vs. PRE, i.e. a large 
proportion of the identified changes in gene expression induced by the 4-day intervention was reversed by the 
3-day period with isoenergetic diet and limited exercise. All differentially expressed genes (FDR < 5%) in WCR 
vs. PRE and DIET vs. WCR are reported in Supplementary Tables S2 and S3, respectively.
A severely energy deficient state leads to increased muscle expression of NNMT and elevated 
circulating levels of N1-methylnicotinamide. The most consistently increased expression at WCR ver-
sus PRE was seen for the NNMT gene, i.e. the gene with the largest increase in expression in all 3 muscle tis-
sues. The increased expression of NNMT was confirmed at the protein level using western blot with a ~12-fold 
(p < 0.001), ~8-fold (p < 0.01) and ~19-fold (p < 0.001) increase for non-exercised and exercised arm and leg 
muscles respectively (n = 15, Fig. 1a). NNMT is a methyltransferase, catalyzing N-methylation of nicotinamide 
(NA) to produce N1-methylnicotinamide (MNA) and has recently been shown to regulate energy expenditure 
with elevated expression in white adipose tissue (WAT) of obese and diabetic mice13. We therefore investigated 
if the severely energy deficient state, induced by the diet and exercise intervention, would result in a difference 
in circulating plasma levels of nicotinamide (pNA) and/or N1-methylnicotinamide (pMNA) using liquid chro-
matography coupled to mass spectrometry (LC-MS). Blood samples were drawn in the fasted state (12 h) at 5 
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different time points. No difference in pNA concentration was observed (Fig. 1b), but the concentration of pMNA 
was ~2-fold increased at WCR compared to before the intervention, i.e. compared to the average pMNA concen-
tration at time points −7 and 0 days (0.24 ± 0.024 μM vs. 0.12 ± 0.010 μM, p < 0.01, n = 15, Fig. 1b).
The nutritional state regulates pMNA levels. To test if the nutritional state alone, regardless of exercise, 
influences the circulating pMNA level, C57BL6/J mice were subjected to either a 4 h or 12 h fasting period. The 
food was withdrawn in the morning (n = 6) and one set of mice was sacrificed after 4 h (n = 4) and a second set 
after 12 h (n = 6). In the fed state (time = 0), the pMNA concentration was 0.15 ± 0.019 μM and increased after 4 h 
to 0.32 ± 0.018 (p < 0.01, Supplementary Fig. S2). After 12 h of fasting the level was 0.22 ± 0.012 μM.
To test if feeding regulates the pMNA level also in humans, 18 healthy Danish volunteers were subjected to a 
36 h fast followed by a meal. The study has previously been described14 and characteristics of the included indi-
viduals are presented in Supplementary Table S4. Blood was drawn at 12, 18, 27 and 36 h of fasting and at 1.5 and 
3 h after the meal. The pMNA level initially increased with duration of fasting (0.12 ± 0.019 μM at 12 h, p < 0.05, 
compared to 0.07 ± 0.009 i.e. the mean of [36 h, 1.5 h and 3 h post meal]), reaching a highest concentration at 
18 h of fasting (0.20 ± 0.029 μM, p < 0.001, compared to 0.07 ± 0.009 i.e. the mean of [36 h, 1.5 h and 3 h post 
meal])—(Fig. 2). Extending the fasting period further led to a reduction of the pMNA concentration, reaching a 
lower-limit of 0.071 ± 0.0099 μM after 27 h of fasting (Fig. 2). Eating a meal after 36 h of fasting, when the pMNA 
concentration was 0.068 ± 0.010 μM, did not lower pMNA further (0.078 ± 0.016 μM and 0.063 ± 0.012 μM at 
1.5 h and 3 h post meal, respectively, Fig. 2). In another experiment 13 healthy Danish volunteers were subjected 
to a 15 h fast followed by a meal. Characteristics of the participants are presented in Supplementary Table S5. 
Six of the volunteers participated in both experiments. After 10 h of fasting the pMNA concentration was 
0.18 ± 0.063 μM. A meal, given after 15 h of fasting, yielded a lower pMNA concentration of 0.096 ± 0.016 μM 
1.5 h after the meal (Supplementary Fig. S3). This level decreased further at 3 h after the meal to 0.063 ± 0.012 μM, 
p < 0.05 compared to 10 h of fasting (Supplementary Fig. S3).
Increased pMNA stimulates lipolysis, but not glucagon or insulin secretion. Having established 
an effect of energy availability on the circulating pMNA level, we hypothesized that MNA could coordinate 
metabolism as a cross-tissue signalling molecule able to mobilize energy substrates from stores in WAT and the 
liver as MNA has been shown to stimulate glucose release from isolated mouse hepatocytes15. An effect on lipoly-
sis has not been shown. Therefore, we also investigated the impact of increased MNA on lipolysis in isolated pri-
mary rat adipocytes. Glycerol release was measured both at non-stimulated and isoproterenol-stimulated (10 nM) 
conditions with addition of 1, 10 or 100 mM MNA. In the basal state, 100 mM MNA increased glycerol release 
~14-fold compared to control (0.10 ± 0.0045 vs. 0.0072 ± 0.0011 μmol/30 min/ml, p < 0.001, n = 6–10, Fig. 3a). In 
the isoproterenol-stimulated state, 100 mM MNA increased glycerol release ~1.5-fold compared to isoproterenol 





















Top 10 up-regulated genes
 NNMT 4837 5.35 0.00623 HMGCS2 3158 5.51 0.03552 ACTC1 70 5.77 0.00023
 HMGCS2 3158 4.64 0.02902 NNMT 4837 4.15 0.03968 MT2A 4502 4.47 0.00010
 PDK4 5166 4.43 0.00526 HMOX1 3162 3.77 0.02117 ANGPTL4 51129 3.90 0.00101
 FCN3 8547 2.87 0.01057 ANGPTL4 51129 3.69 0.02170 CDKN1A 1026 3.01 0.01522
 TPPP3 51673 2.83 0.00085 C13ORF39 196541 3.67 0.01396 NNMT 4837 2.93 0.00851
 RHOD 29984 2.50 0.02892 TPPP3 51673 2.70 0.00332 HMOX1 3162 2.92 0.00186
 UCP2 7351 2.22 0.00563 UCP2 7351 2.66 0.00022 SERPINA3 12 2.81 0.00149
 GLRX 2745 2.10 0.01057 FCN3 8547 2.53 0.01693 PDK4 5166 2.77 0.00636
 CEBPD 1052 2.03 0.02448 RHOD 29984 2.38 0.04033 LOC644150 644150 2.71 4.30E-06
 MPP6 51678 1.78 0.01057 IRF7 3665 2.25 0.00959 FCN3 8547 2.56 0.00016
Top 10 down-regulated genes
 TFRC 7037 0.17 0.00085 TFRC 7037 0.15 6.04E-07 TFRC 7037 0.19 2.56E-05
 TMEM70 54968 0.32 0.00488 TMEM70 54968 0.30 0.01396 C5ORF13 9315 0.22 8.45E-09
 WDR62 284403 0.34 0.00623 G0S2 50486 0.36 0.04413 ITGB1BP3 27231 0.22 0.00073
 OR7E37P 100506759 0.37 3.54E-05 OR7E37P 100506759 0.39 5.06E-07 SLC16A3 9123 0.23 1.68E-05
 FLJ25404 146378 0.37 0.01057 C5ORF13 9315 0.40 0.00311 ZNF197 10168 0.25 0.00023
 EXTL1 2134 0.38 0.00488 WDR62 284403 0.41 0.01396 WDR62 284403 0.26 7.19E-05
 MASP1 5648 0.38 0.02448 EXTL1 2134 0.41 0.00109 OR7E37P 100506759 0.30 8.45E-09
 C5ORF13 9315 0.39 0.01057 ATPGD1 57571 0.45 0.00146 ATPGD1 57571 0.30 2.60E-07
 ATPGD1 57571 0.43 0.00450 CA14 23632 0.45 0.00446 LOC342934 N/A 0.31 0.00074
 CA14 23632 0.44 0.00344 MAP6D1 79929 0.48 0.00446 ANK1 286 0.31 4.15E-12
Table 1. Top 10 genes ranked on fold change (up or down) in skeletal muscle from non-exercised arm (deltoid), 
exercised arm and leg (vastus lateralis) following a 4-day intervention (PRE vs. WCR).
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alone (0.19 ± 0.0043 vs. 0.13 ± 0.014 μmol/30 min/ml, p < 0.01, n = 6–10, Fig. 3a). Isoproterenol alone stimulated 
glycerol release ~18-fold (p < 0.001, n = 10, Fig. 3a). To test if MNA exerts its effects primarily on WAT and the 
liver or if its regulation of lipolysis and glucose production could be mediated via glucagon and/or insulin, hor-
mone secretion was measured from human pancreatic islets of Langerhans stimulated with 1–100 mM of MNA. 
However, no effect of MNA on either glucagon or insulin release was found (Fig. 3b,c).
Isolated human myotube cells have the ability to secrete MNA. Next, we analyzed the expression of 
NNMT in muscle cells, and more importantly if muscle cells are able to secrete MNA. Human myotubes were cul-
tured for 48 and 72 h in two different media, i.e. α-MEM or F10. Two culture conditions were chosen for replica-
tion purposes and the main difference in composition between the two media was the amount of included amino 
acids and NA, e.g. α-MEM medium contains ~1.7-fold higher NA concentration compared to F10. The mRNA 
expression level of NNMT and the concentration of MNA in the culture medium were measured. No difference in 
myotube NNMT mRNA expression was seen between the two time points (48 and 72 h) in either of the two media 
Figure 1. NNMT protein levels in skeletal muscle and MNA/NA plasma concentrations in humans during 
a 4-day low-caloric-high-volume exercise intervention. (a) Protein expression of NNMT in human skeletal 
muscle measured using Western blot before (PRE), after (WCR) and at 3 days post (DIET) a 4-day low-caloric-
high-volume exercise intervention. Expression in the non-exercised arm, exercised arm and leg are given 
separately. A quality control sample was included on all gels (Ctr). Top square image shows a representative 
NNMT band (~30 kDa) (blot was cut on either side of the band before staining with antibody). Lower image is 
cropped from the full-length blot stained with reactive brown (for image of full-length blot, see Supplementary 
Fig. S6), and shows the region of the blot that was cut and stained with NNMT antibody. **p < 0.01, 
***p < 0.001 using Wilcoxon signed-rank tests compared to PRE, (n = 15). No significant difference between 
WCR and DIET was observed. (b) Circulating levels of plasma nicotinamide (NA) and N1-methylnicotinamide 
(MNA) at five time point before and after the 4-days intervention, (n = 15). The intervention period is indicated 
with grey shading. Blood was drawn after 12 h of fasting at each time point. **p < 0.01 using Wilcoxon signed-
rank tests compared to the average level of the two time points before the intervention. No significant difference 
in NA concentration was observed. Data is given as mean ± SEM.
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(10.65 ± 1.51 AU vs. 11.99 ± 1.53 AU [α-MEM] and 13.39 ± 1.94 vs. 15.34 ± 4.28 [F10], or between the two media 
at either time point (10.65 ± 1.51 AU vs. 13.39 ± 1.94 [48 h] and 11.99 ± 1.53 AU vs. 15.34 ± 4.28 [72 h], n = 5 
in 1–3 independent experiments, Fig. 4a). However, the concentration of MNA in the medium was increased 
by 1.7-fold and 1.9-fold at 72 h vs. 48 h in both α-MEM medium (1.06 ± 0.17 vs. 0.61 ± 0.11 μM/μg RNAtot, 
p < 0.05, n = 5 in 1–3 independent experiments) and in F10 medium (1.95 ± 0.27 vs. 1.04 ± 0.19 μM/μg RNAtot, 
p < 0.01, n = 5 in 1–3 independent experiments), respectively (Fig. 4b). Interestingly, increased levels of MNA 
was observed in F10 compared to α-MEM medium, showing a 1.8-fold increase at 72 h of culture (1.95 ± 0.27 
vs. 1.06 ± 0.17 μM/μg RNAtot, p = 0.056 with a Mann-Whitney U test, n = 5 in 1–3 independent experiments, 
Fig. 4b), indicating that the concentration of amino acids may influence muscle MNA secretion. No difference 
in the concentration of NA was seen between the two time points in either medium (Supplementary Fig. S4). To 
screen for metabolites correlating with the release of MNA, we measured the concentration of 47 metabolites 
in the media using LC-MS after culturing human myotubes as described above, i.e. with combination of dif-
ferent durations (48 and 72 h) and media (α-MEM and F10) (Supplementary Fig. S5). 2-Hydroxybutanoic acid 
(i.e. α-Hydroxybutyrate, α-HB) was the most correlated metabolite with MNA in α-MEM medium (α-MEM: 
r2 = 0.93 [48 h] and 0.64 [72 h]; F10: r2 = 0.009 [48 h] and 0.010 [72 h] (Fig. 4c)).
Discussion
In this study, we examined changes in skeletal muscle gene expression after caloric restriction in combination 
with an exercise intervention. The expression of key genes involved in metabolic regulation (e.g. CPT2, PDK4 
and PFKFB3) was altered after the 4-day intervention, indicating a shift from carbohydrate to fat metabolism. 
As expected, we observed an increased expression of PDK4 after the 4-day intervention, indicating a low car-
bohydrate oxidation rate, as PDK4 is an inhibitor of the pyruvate dehydrogenase complex (PDC) and thereby 
the transport of pyruvate into the mitochondria. An increased lipid oxidation rate was also supported by the 
increased expression of CPT2, an important part of the transport system of fatty acids into the mitochondria. The 
results also indicate increased muscle wasting, i.e. increased expression of genes involved in the ubiquitine pro-
teasome system (e.g. TRIM63 and PSMD4), as well as in the autophagy-lysosomal proteolytic system (e.g. BNIP3, 
CTSD and SQSTM1). A majority of the changes observed were however reversed by 3 days of isoenergetic diet 
and limited exercise.
The major finding was that the expression of NNMT in skeletal muscle was consistently increased after the 
intervention with a concomitant increase of pMNA. In connection, nicotinamide riboside kinase 2 (ITGB1BP3) 
and poly [ADP-ribose] polymerase 1 (PARP1), proteins involved in the NAD+-salvage pathway, were found to 
have lower expression after the intervention. Fasting alone increased the pMNA concentration and eating a meal, 
when pMNA was high, reduced pMNA to approximately 0.07 μM after 3 h. Interestingly, while the concentration 
of NA was not significantly changed at the severely energy deficient state (Fig. 1b), a concomitant increase in NA 
was seen with the increase of MNA in response to fasting alone (Fig. 2). NNMT has recently been shown to regu-
late energy expenditure with elevated expression in WAT in obese and diabetic mice13. Knockdown of NNMT in 
WAT and liver in mice protects against diet-induced obesity by increasing cellular energy expenditure. However, 
these experiments were not performed in tissue-specific mouse models and a possible effect of skeletal muscle 
NNMT knockdown was not considered13. Chronic MNA treatment lowers fasting glucose levels and prolongs the 
survival of rats with streptozotocin-induced diabetes16. Patients with T2D show approximately two fold higher 
expression of NNMT in WAT compared to healthy controls17 and elevated levels of MNA both in the circula-
tion17,18 and in urine19. The pMNA level is positively correlated with BMI17,19, inversely with insulin sensitivity17 
and bariatric surgery has been shown to reduce both WAT NNMT expression and the level of pMNA17. In liver, 
NNMT is a positive regulator of gluconeogenesis, via a sirtuin 1-dependent mechanism and MNA stimulates 
gluconeogenesis in primary hepatocytes15. In addition, here we show that MNA also has the ability to stimulate 
lipolysis in isolated rat adipocytes, but has no effect on the release of insulin or the starvation hormone glucagon 
from human islets of Langerhans. Out of the 47 measured metabolites in media from cultured human myotubes, 
Figure 2. Plasma MNA and NA levels in humans during fasting and feeding. Circulating levels of plasma 
MNA and NA after prolonged fasting (36 h) and refeeding. *p < 0.05, **p < 0.01, ***p < 0.001 using Wilcoxon 
signed-rank tests. Time points 12 h, 18 h and 27 h of fasting are compared to the mean level of time points 36 h 
fasting, 1.5 h post feeding and 3 h post feeding, n = 18. Data is given as mean ± SEM.
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the MNA concentration was most strongly correlated with that of α-HB. α-HB has been suggested to be an 
early biomarker of insulin resistance and a predictor of glucose intolerance20,21. The results presented here clearly 
demonstrate that the NNMT-MNA axis plays an important role as a regulator of energy metabolism, supported 
by previous studies13,15,17. In addition, data presented in literature13,16–19 also show that a perturbation of this 
mechanism is seen in obesity and T2D. Taken together, these results suggest that pMNA could be a potential 
biomarker for metabolic flexibility22,23 and possibly be used as an early marker for metabolic disease.
Figure 3. Measurements of the effect of MNA on rat lipolysis and human glucagon and insulin secretion.  
(a) Lipolysis in isolated rat adipocytes. Primary adipocytes were pre-incubated with MNA (1–100 mM) 
for 30 min, and then stimulated with isoproterenol (Iso, 10 nM) for additional 30 min. Glycerol release was 
measured in the medium both in the unstimulated and Iso-stimulated state, n = 6–10 independent experiments 
of pools of 2–3 rats per experiments. (b) Glucagon secretion from human islets of Langerhans, n = 3–5. (c) 
Insulin secretion from human islets of Langerhans, n = 4. *p < 0.05, **p < 0.01, ***p < 0.001 using Kruskal–
Wallis tests with Dunn’s correction for multiple comparisons within each group (Ctrl and Iso). Data is given as 
mean ± SEM.
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Here we show an increase of muscle NNMT protein and pMNA concentrations after exercise and caloric 
restriction. It has previously been reported that a 12-week exercise intervention led to a reduction of WAT NNMT 
expression in prediabetic and diabetic individuals, but no change in healthy controls17. The effect on pMNA 
was not measured. In contrast, a single bout of endurance exercise increased liver NNMT activity and pMNA24. 
However, the increased pMNA level observed after exercise could not be explained by the regulation of liver 
NNMT, as liver NNMT activity was not increased after exercise in IL-6 knockout mice, but yet led to an increase 
of pMNA24. Although adipocytes have been shown to secrete MNA25, the increased pMNA seen after exercise 
cannot be explained by expressional regulation of NNMT in WAT or the liver. The data presented here suggest 
that this elevated pMNA concentration could be explained by release of pMNA from skeletal muscle under exer-
cise and/or fasting conditions. However, in the metabolically unhealthy, i.e. obese, prediabetic or T2D states, a 
correlation between WAT NNMT expression and the fasting pMNA level have been described17, indicating that 
a dysregulation of the NNMT-MNA axis in WAT may play a greater role under such conditions. How regulation 
of muscle NNMT activity influences metabolism in prediabetic and diabetic individuals remains to be studied, 
as all individuals examined here were non-diabetic. However, the duration of fasting should be considered in 
all comparisons, as our results showed an initial increase and subsequent decrease in pMNA levels after fasting.
Caloric restriction and weight reduction have many positive effects on metabolism and also increase liver 
NNMT expression in mice15,26. Here we show a similar regulation of NNMT expression in human skeletal mus-
cle. This is in contrast to WAT NNMT expression, which is reduced by weight reduction17. Thus, the regula-
tory mechanisms of NNMT expression as well as the mechanisms underlying the downstream effects are most 
likely different in these tissues. In line with the regulation in liver15, we postulate that the downstream effects 
of muscle NNMT activity are not mediated by a shift in the methyl donor balance, as in WAT13, but rather by 
its product MNA. The muscle energy-sensing mechanism is however unclear, but possibly involves a signal 
emanating from the balance between anaerobic and aerobic metabolism, or a shift from carbohydrate to lipid 
oxidation. Caloric restriction elicits increased activity of proteins in the sirtuin family (e.g. Sirt1)27, which in 
turn results in lysine deacetylation and breakdown of nicotinamide adenine dinucleotide (NAD+) to NA and 
1′-O-acetyl-ADP-ribose28 or 2′- and 3′-O-acetyl-ADP-ribose29. An increased activity of NNMT during such 
low-energy states could serve to maintain a high degree of deacetylase activity and fat oxidation by removing 
NA and thereby its feedback-inhibition of Sirt130. NNMT may thus serve as a sensor for the change in the redox 
Figure 4. NNMT mRNA expression, and the release of MNA and α-Hydroxybutyrate from human myotubes. 
(a) The mRNA expression level of NNMT in human myotube cells measured using QPCR. The myotubes were 
cultured in either α-MEM or F10 medium for 48 h or 72 h. n = 5 in 1–3 experiments. (b) Concentration of 
MNA in human myotube culture medium. n = 4–5 in 1–3 experiments. The MNA concentration is expressed 
versus total RNA content to normalize for cell density. (c) Concentration of MNA and α-Hydroxybutyrate in 
the culture medium after 48 h or 72 h incubation in either α-MEM or F10 medium. n = 4 in 1–3 independent 
experiments. *p < 0.05, **p < 0.01 using Paired t tests. Data is given as mean ± SEM.
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system of the cell. The level of circulating amino acids could possibly play a part in the muscle energy-sensing 
mechanism, as indicated by the experiments in myotubes showing higher concentration of MNA in the amino 
acid poor F10 medium (Fig. 4b).
In summary, we have shown that a high-volume-low-intensity exercise intervention in combination with 
caloric restriction elevates the expression of NNMT in human skeletal muscle, and that this increase is mirrored 
by a rise in the fasting level of pMNA. The pMNA level can also be regulated by the nutritional state alone, i.e. 
fasting leads to an initial increase followed by a decline, while eating a meal when the pMNA level is high lowers 
this level. MNA can be secreted from human myotubes and stimulates lipolysis, but has no effect on glucagon 
or insulin release. On the basis of these findings and the existing literature, we propose that MNA is a myokine 
that signals directly to WAT and the liver to mobilize energetic substrates when the availability of energy is low in 
muscle. Future research should focus on applying MNA as a biomarker for skeletal muscle insulin sensitivity to 
identify individuals with metabolic disturbances at an early stage.
Methods
Participants. The Ostersund study10 was designed to get insight into the mechanisms that regulate muscle 
metabolism, muscle mass and fat mass during severe energy deficit in humans. To isolate the potential effects due 
to exercise from those elicited by the neuro-endocrine systemic adaptations, muscle biopsies were obtained from 
three different skeletal muscles subjected to different levels of exercise. The inclusion criteria were: 1) an age of 
18–55 years, 2) stable body weight for at least 3 months prior to the start of the experiments, 3) a BMI ≥ 25 kg/m2, 4) 
a waist circumference >102 cm, and 5) 20–40% body fat. The exclusion criteria were: 1) orthopedic limitations 
incompatible with prolonged walking or exercise, 2) smoking and 3) chronic disease of any kind. Sixteen men 
were recruited initially, but one retired due to incompatibility with his working duties. The 15 remaining partic-
ipants were assigned randomly to a diet consisting of either sucrose (n = 7) or whey protein (n = 8) during study 
phase III. Characteristics of participants are presented in Supplementary Table S1. The study was divided into five 
different phases: I = baseline assessment (PRE), II = intervention (WCR), III = recovery (DIET), IV = follow up 
4 weeks post intervention (4W) and V = follow up 1 year post intervention (1Y). The 4-day intervention during 
phase II consisted of walking, arm cranking exercise + caloric restriction. The 3-day recovery during phase III 
consisted of isocaloric diet and reduced exercise (maximum 10000 steps per day). During phase I and at the end of 
phases II, III and IV, body composition (Lunar iDXA, GE Healthcare, Madison, WI; and Bioimpedance, InBody 
720, Biospace Co. Ltd, Seoul, Korea) and VO2max using a metabolic cart (Jaeger Oxycon Pro, Viasys Healthcare, 
Hoechberg, Germany) during an incremental exercise test to exhaustion on a cycle ergometer (Monark 839E, 
Ergomedic, Sweden) were assessed. In addition, during phases I-IV 30-ml blood samples were drawn, following 
a 12 h overnight fast. In phase I, blood samples were obtained on two occasions, one week apart. During phase V, 
only body composition was assessed. A full description of the experimental protocol can be found elsewhere10.
The 36 h fasting study has previously been published14. Briefly, 18 men (age = 24.6 ± 1.2 years and 
BMI = 22.9 ± 3.2 kg/m2) were recruited from the Danish National Birth Registry as healthy, non-diabetic, with no 
diabetes in two family generations. Characteristics of the participants are presented in Supplementary Table S4. 
All were subjected to 36 h of fasting and sampling. 8–16 weeks after the 36 h fasting study, 6 of these subjects 
participated in a second study together with 7 other matched males born with a low birth weight. Characteristics 
of the participants are presented in Supplementary Table S5. The 13 participants received a control diet and were 
subjected to a 15 h fast. During both study settings, the participants were allowed ad-libitum water. For 72 h 
prior to the study interventions, the participants received a control diet of precooked meals for standardization 
of energy intake (10 MJ per day, 50% carbohydrate, 35% fat, 15% protein). Furthermore, the participants were 
not allowed to perform exercise or consume alcohol or soft drinks in these three days. All blood samples were 
immediately distributed into tubes, placed on ice, and centrifuged (Eppendorf Centrifuge 5810R, Eppendorf AG, 
Hamburg, Germany). Plasma was obtained and stored at −80 C until later analysis.
Microarray analysis of muscle biopsies. Fifteen overweight Swedish men participated in a 4-day inter-
vention combining severe caloric restriction with prolonged exercise, as previously described. Muscle biopsies 
were obtained from right and left deltoid muscle and from vastus lateralis of either leg. RNA was extracted from 
10–20 mg of muscle biopsies using a TissueLyser II (Qiagen) and the RNeasy Fibrous Tissue mini kit (Qiagen). 
RNA concentration was estimated using a NanoDrop ND-1000 spectrophotometer (A260/A280 > 1.8 and A260/
A230 > 1.0 (NanoDrop Technologies, Wilmington, DE, USA). RNA integrity was evaluated using the 2100 
Bioanalyzer Instrument (Agilent Technologies). Input RNA, 100 ng for the leg and 200 ng for the arm samples, 
was used for subsequent biotinylation and hybridization. TotalPrep™-96 RNA Amplification Kit (Thermo Fisher 
Scientific) was used to generate biotinylated, amplified cRNA for subsequent hybridization of 750 ng (150 ng/µl) 
on the Human HT-12 v4 Expression BeadChip (Illumina) and scanning on the iScan system (Illumina). The 
raw data was read and quantified using Illumina Genome Studio version 1.1.1. Summary level expression data 
was read using the Bioconductor beadarray package. Differential expression analysis was performed using the 
Bioconductor limma package. P-values were corrected using the False Discovery Rate method, with an accept-
ance of < 0.05.
Total protein extraction, electrophoresis, and Western blot analysis. Protein extracts from the 
muscle biopsies were prepared as previously described31, and total protein content was quantified using the bicin-
choninic acid assay32. Briefly, proteins were solubilized in sample buffer containing 0.0625 M Tris-HCl (pH 6.8), 
2.3% (wt/vol) sodium dodecyl sulfate (SDS), 10% (vol/vol) glycerol, 5% (vol/vol) β-mercaptoethanol, and 0.001% 
(wt/vol) bromophenol blue. The total protein to load and the optimal antibody concentration was determined 
by linear regression from a gradient of protein extracts at concentrations ranging from 20 to 45 μg. The lin-
ear relation between total protein concentration loaded and quantitative intensity of the bands was calculated. 
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After confirming linearity in this range, equal amounts (30 μg) of each sample were electrophoresed with 10% 
SDS-PAGE as previously described33 and transferred to an Immun-Blot PVDF Membrane for Protein Blotting 
(Bio-Rad Laboratories). To control for differences in loading and transfer efficiency across membranes, mem-
branes were stained with Reactive Brown 10 (0.07%) and destained with water for 10 sec to remove background. 
Loading was similar for control and experimental samples (data not shown). After this, membranes were 
destained for 3 × 10 min in NaOH (0.1 N). To determine NNMT total protein amount, the membrane, cut on 
either side of the region for the NNMT band (~30 kDa), was incubated with an antibody directed against NNMT 
(NNMT (G-4), a mouse monoclonal antibody raised against NNMT of human origin, sc-376048, Santa Cruz 
Biotechnology), diluted (1:1000) in 4% BSA, in Tris-buffered saline with 0.1% Tween 20 (TBS-T; BSA-blocking 
buffer). Antibody-specific labelling was revealed by incubation with goat anti-mouse IgG-HRP (sc-2031, Santa 
Cruz Biotechnology), diluted (1:5000) in 5% blocking buffer, and visualized with the ClarityTM Western ECL 
Substrate kit (Bio-Rad Laboratories) using the ChemiDoc XRS system (Bio-Rad Laboratories) and analysed with 
Quantity One (Bio-Rad Laboratories). Densitometry analyses were carried out immediately. Samples from each 
subject were run on the same gel. In addition, in all gels, a 30 μg control sample obtained from the extraction of 5 g 
of pooled human skeletal muscle from different healthy donors was loaded 4 times per gel as an internal control.
Measurements of pMNA and NA using LC-MS. Measurements of 1-methylnicotinamide were per-
formed in human serum, mouse EDTA plasma and cell media using a UHPLC-QTOF-MS System (Agilent 
Technologies 1290 LC, 6550 MS, Agilent Technologies, Santa Clara, CA, USA). All samples were stored at −80 °C 
and thawed on ice before metabolite extraction was performed by addition of six volumes of extraction solvent, 
consisting of 80:20 LC-MS grade methanol/water containing the stable isotope labelled 1-methylnicotinamide-d4 
(Toronto Research Chemicals Inc., Toronto, Canada). Samples were incubated at 4 °C, with mixing at 1250 rpm 
during 1 hour, before precipitated proteins were removed by centrifugation for 20 minutes at 14000 × g. The 
supernatant was transferred to glass vials. Sample preparation for measurement of α-HB in cell media was per-
formed in the same manner. Liquid chromatography separation was performed by injecting 2 µl sample on an 
Acquity UPLC BEH Amide column (1.7 μm, 2.1 * 100 mm; Waters Corporation, Milford, MA, USA) or on an 
ACE C18 column (1.7 μm, 2.1 * 100 mm; Advanced Chromatography Technologies Ltd., Aberdeen, UK) for 
measurements of 1-methylnicotinamide and α-HB respectively. Separation on Acquity UPLC BEH Amide was 
performed by gradient elution using two mobile phases (mobile phase A: H2O with 10 mM ammonium formate 
and 0.1% formic acid; mobile phase B: acetonitrile with 0.1% formic acid) using a flow rate of 0.4 ml/min and 
subsequent mass spectrometric analysis was performed in positive electrospray ionization. Gradient elution on 
ACE C18 (mobile phase A: H2O with 0.1% formic acid; mobile phase B: acetonitrile with 0.1% formic acid) was 
performed with at flow rate of 0.3 ml/min and subsequent mass spectrometric analysis utilized negative electros-
pray ionization. The auto sampler was kept at 16 °C. The sheath gas temperature was set at 350 °C and the sheath 
gas flow at 12 l/min. The drying gas flow was 14 l/min and was delivered at 200 °C. Mass spectra were acquired at a 
rate of 1 spectra/s and the mass range was 70–1000 m/z (mass-to-charge ratio). Samples were analysed in batches 
of maximum 45 samples, where pooled QC samples were injected every 5 samples and in the beginning of each 
batch to ensure high repeatability and to condition the LC-column respectively.
Adipocyte isolation and lipolysis assay. To measure lipolysis, rat adipocytes were isolated from epididy-
mal fat tissue, as described previously34. Cells were suspended (10% suspension) in Krebs-Ringer (KRH) medium 
containing 25 mM Hepes pH 7.4, 200 nM adenosine and 1% BSA (w/v), preincubated with MNA (1–100 mM) 
for 30 min, and then stimulated with isoproterenol (Iso, 10 nM) for additional 30 min as indicated in the fig-
ures (at 37 °C, with shaking, 150 cycles/min). After 30 min, samples were placed on ice for 20 min, and 200 µl of 
the cell medium was subsequently removed for enzymatic determination of the glycerol content, as described 
previously35.
Glucagon and insulin secretion measurements in isolated human islets of Langerhans. Islets 
from 6 human donors (gender = F3/M3, age 55 ± 7, BMI 26.5 ± 2.0 kg/m2, HbA1c 5.9 ± 0.1, days in culture 
2.8 ± 0.6) were provided by the Nordic Network for Clinical Islet Transplantation (Uppsala, Sweden). Human 
islets were hand-picked to ensure high purity. Insulin and glucagon secretion was measured in static batch incuba-
tions described previously36. Briefly, batches with 12 islets (in quadruplicates) were pre-incubated in Krebs Ringer 
solution (120 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl22H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4, 10 mM HEPES, 
25 mM NaHCO3, pH 7.4, supplemented with carbogen and 1 mg/ml of bovine serum albumin) supplemented 
with 1 mM glucose for 30 min, followed by 1 h incubation at 2.8 and 16.7 mM glucose in absence or presence of 
MNA (1–100 mM) as indicated. Insulin secretion was measured using radioimmunoassay kit (Euro-Diagnostica, 
Malmö, Sweden) and glucagon secretion was measured with ELISA (Mercodia, Uppsala, Sweden).
Culturing of human myotubes. Human primary Skeletal Muscle Derived Cells (SkMDC) from five dif-
ferent donors were purchased from Cook Myosite (Pittsburg, US). The myoblast cells were cultured and differ-
entiated into myotubes following instructions supplied by the vendor. Briefly, cells were maintained in growth 
basal medium with growth supplements (MK-2288; Cook Myosite), 10% fetal calf (FCS) serum (Thermo Fisher 
Scientific) and antibiotics (0.4% penicillin/streptomycin (P/S). Cells were passaged at ~50% confluence. To induce 
differentiation, cells were plated at ~45000 cells/cm2 in 6-well plates. Growth media was replaced with differen-
tiation media (MD-9999; Cook Myosite) with 2% FCS and 0.4% P/S, and the cultures were incubated for 3 days, 
during which time myotube differentiation occurred (monitored using the expression of differentiation markers, 
i.e. Myosin Heavy Chain 2 and Myocyte-specific enhancer factor 2C). After differentiation, the multinucleated 
myotubes were either cultured in α-Minimum Essential Medium (α-MEM) or Ham’s F10 Nutrient Mix (F10) 
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(Thermo Fisher Scientific; catalog numbers 22571 and 31550 respectively) for 48 h or 72 h, containing 2% FCS 
and 0.4% P/S. At each time point, total RNA was extracted from the cell cultures.
Quantitative real-time PCR. RNA was isolated from the muscle cells using the RNeasy Fibrous Tissue 
Mini Kit (Qiagen), and DNA was removed on-column using the RNase-Free DNase Set (Qiagen). Concentration 
and purity was measured using a NanoDrop ND-1000 spectrophotometer (A260/A280 > 1.8 and A260/A230 > 1.0) 
(NanoDrop Technologies, USA). RNA integrity was verified using the 2200 TapeStation instrument (Agilent 
Technologies, CA, US). Reverse transcription was performed on 0.2 µg RNA using the QuantiTect reverse tran-
scription kit (Qiagen). QPCR was carried out using an ABI 7900HT sequence detection system with 10 ng cDNA 
in 10 µl reactions and TaqMan Expression PCR Master Mix with duplex assays according to the manufacturer’s 
recommendations (Applied Biosystems, Thermo Fisher Scientific). All samples for each gene were analyzed in 
triplicates on the same 384 well plate (maximum accepted standard deviation in Ct-value of 0.1 cycles) with 3 
endogenous controls (POLR2A, HPRT1 and CYCA). Probe sets used: NNMT (Hs00196287_m1). Endogenous 
control probe sets: POLR2A (Hs00172187_m1), HPRT1 (4326321E, VIC-MGB) and CYCA (4326316E, 
VIC-MGB).
pMNA in mice during fasting. Male C57BL/6J mice (Taconic, Ry, Denmark) were used at 10–12 weeks 
of age. Animals were on a 12 h light cycle with non-restricted food (chow) and water. Food was withdrawn in 
the morning and blood was sampled through Vena Saphena for serum analysis following 0, 4 or 12 h of fasting 
(n = 4–6 animals/time point). Each animal was sacrificed following blood sampling.
Statistical analysis. Differences between group medians were analyzed using Mann-Whitney U tests or 
Kruskal-Wallis test with Dunn’s correction for multiple comparisons where appropriate. Analysis of paired data, 
i.e. repeated measures on the same sample, were performed using Wilcoxon signed-rank test. Correlations were 
calculated using Spearman’s method. In all tests p < 0.05 was considered statistically significant. Data was ana-
lyzed with SPSS 19.0 (SPSS, Chicago, IL, USA) and Graphpad 7 (Graphpad software, La Jolla, CA, USA).
Accordance. The methods were carried out in accordance with the relevant guidelines and regulations.
Study approval and informed consent. The Ostersund study was approved by the Regional Ethical 
Review Board of Umeå University (Umeå, Sweden), as well as the ethical committee of the University of Las 
Palmas de Gran Canaria (Canary Islands, Spain). All participants provided written consent after being informed 
about potential risks and benefits, prior to inclusion in the study.
The study designs and protocols in the 36 h and 15 h fasting studies were approved by the local ethics com-
mittee and applied to the Helsinki II declaration. Informed consent was obtained from the participants prior to 
the study.
The local ethics committee in Lund/Malmö approved the use of material from deceased human donors for the 
glucagon and insulin secretion measurements in isolated human islets of Langerhans, and all animal experiments.
Data availability. The datasets generated during and/or analysed during the current study are available from 
the corresponding author on reasonable request.
References
 1. Stewart, S. T., Cutler, D. M. & Rosen, A. B. Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med 361, 
2252–2260, https://doi.org/10.1056/NEJMsa0900459 (2009).
 2. Association, A. D. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 36, 1033–1046, https://doi.org/10.2337/dc12-2625 
(2013).
 3. Shaw, K., Gennat, H., O’Rourke, P. & Del Mar, C. Exercise for overweight or obesity. Cochrane Database Syst Rev, CD003817, https://
doi.org/10.1002/14651858.CD003817.pub3 (2006).
 4. Washburn, R. A. et al. Does the method of weight loss effect long-term changes in weight, body composition or chronic disease risk 
factors in overweight or obese adults? A systematic review. PLoS One 9, e109849, https://doi.org/10.1371/journal.pone.0109849 
(2014).
 5. Foster-Schubert, K. E. et al. Effect of diet and exercise, alone or combined, on weight and body composition in overweight-to-obese 
postmenopausal women. Obesity (Silver Spring) 20, 1628–1638, https://doi.org/10.1038/oby.2011.76 (2012).
 6. Weinheimer, E. M., Sands, L. P. & Campbell, W. W. A systematic review of the separate and combined effects of energy restriction 
and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity. Nutr Rev 68, 375–388, https://doi.
org/10.1111/j.1753-4887.2010.00298.x (2010).
 7. Fisher, F. M. et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev 26, 
271–281, https://doi.org/10.1101/gad.177857.111 (2012).
 8. Wing, R. R. & Hill, J. O. Successful weight loss maintenance. Annu Rev Nutr 21, 323–341, https://doi.org/10.1146/annurev.
nutr.21.1.323 (2001).
 9. Riebe, D. et al. Long-term maintenance of exercise and healthy eating behaviors in overweight adults. Prev Med 40, 769–778, https://
doi.org/10.1016/j.ypmed.2004.09.023 (2005).
 10. Calbet, J. A., Ponce-González, J. G., Pérez-Suárez, I., de la Calle Herrero, J. & Holmberg, H. C. A time-efficient reduction of fat mass 
in 4 days with exercise and caloric restriction. Scand J Med Sci Sports 25, 223–233, https://doi.org/10.1111/sms.12194 (2015).
 11. Carbone, J. W., McClung, J. P. & Pasiakos, S. M. Skeletal muscle responses to negative energy balance: effects of dietary protein. Adv 
Nutr 3, 119–126, https://doi.org/10.3945/an.111.001792 (2012).
 12. Zibellini, J. et al. Effect of diet-induced weight loss on muscle strength in adults with overweight or obesity—a systematic review and 
meta-analysis of clinical trials. Obes Rev, https://doi.org/10.1111/obr.12422 (2016).
 13. Kraus, D. et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature 508, 258–262, https://
doi.org/10.1038/nature13198 (2014).
 14. Jørgensen, S. W. et al. Metabolic response to 36 hours of fasting in young men born small vs appropriate for gestational age. 
Diabetologia 58, 178–187, https://doi.org/10.1007/s00125-014-3406-6 (2015).
www.nature.com/scientificreports/
1 1SCIEntIFIC REpORtS |  (2018) 8:3016  | DOI:10.1038/s41598-018-21099-1
 15. Hong, S. et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat Med 
21, 887–894, https://doi.org/10.1038/nm.3882 (2015).
 16. Watała, C. et al. Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats. Pharmacol Rep 61, 
86–98 (2009).
 17. Kannt, A. et al. Association of nicotinamide-N-methyltransferase mRNA expression in human adipose tissue and the plasma 
concentration of its product, 1-methylnicotinamide, with insulin resistance. Diabetologia 58, 799–808, https://doi.org/10.1007/
s00125-014-3490-7 (2015).
 18. Liu, M. et al. Serum N(1)-Methylnicotinamide Is Associated With Obesity and Diabetes in Chinese. J Clin Endocrinol Metab 100, 
3112–3117, https://doi.org/10.1210/jc.2015-1732 (2015).
 19. Salek, R. M. et al. A metabolomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol Genomics 29, 
99–108, https://doi.org/10.1152/physiolgenomics.00194.2006 (2007).
 20. Gall, W. E. et al. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic 
population. PLoS One 5, e10883, https://doi.org/10.1371/journal.pone.0010883 (2010).
 21. Ferrannini, E. et al. Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological 
significance. Diabetes 62, 1730–1737, https://doi.org/10.2337/db12-0707 (2013).
 22. Felber, J. P. & Vannotti, A. Effects of Fat Infusion on Glucose Tolerance and Insulin Plasma Levels. Medicina experimentalis. 
International journal of experimental medicine 10, 153–156 (1964).
 23. Kelley, D. E. & Mandarino, L. J. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49, 677–683 
(2000).
 24. Chłopicki, S. et al. Single bout of endurance exercise increases NNMT activity in the liver and MNA concentration in plasma; the 
role of IL-6. Pharmacol Rep 64, 369–376 (2012).
 25. Riederer, M., Erwa, W., Zimmermann, R., Frank, S. & Zechner, R. Adipose tissue as a source of nicotinamide N-methyltransferase 
and homocysteine. Atherosclerosis 204, 412–417, https://doi.org/10.1016/j.atherosclerosis.2008.09.015 (2009).
 26. Estep, P. W., Warner, J. B. & Bulyk, M. L. Short-term calorie restriction in male mice feminizes gene expression and alters key 
regulators of conserved aging regulatory pathways. PLoS One 4, e5242, https://doi.org/10.1371/journal.pone.0005242 (2009).
 27. Nemoto, S., Fergusson, M. M. & Finkel, T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 306, 
2105–2108, https://doi.org/10.1126/science.1101731 (2004).
 28. Tanner, K. G., Landry, J., Sternglanz, R. & Denu, J. M. Silent information regulator 2 family of NAD- dependent histone/protein 
deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc Natl Acad Sci USA 97, 14178–14182, https://doi.org/10.1073/
pnas.250422697 (2000).
 29. Jackson, M. D. & Denu, J. M. Structural identification of 2′- and 3′-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 
family of beta -NAD+-dependent histone/protein deacetylases. J Biol Chem 277, 18535–18544, https://doi.org/10.1074/jbc.
M200671200 (2002).
 30. Gerhart-Hines, Z. et al. Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1alpha. 
EMBO J 26, 1913–1923, https://doi.org/10.1038/sj.emboj.7601633 (2007).
 31. Guerra, B. et al. Leptin receptors in human skeletal muscle. J Appl Physiol (1985) 102, 1786–1792, https://doi.org/10.1152/
japplphysiol.01313.2006 (2007).
 32. Smith, P. K. et al. Measurement of protein using bicinchoninic acid. Anal Biochem 150, 76–85 (1985).
 33. Laemmli, U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680–685 (1970).
 34. Rodbell, M. METABOLISM OF ISOLATED FAT CELLS. I. EFFECTS OF HORMONES ON GLUCOSE METABOLISM AND 
LIPOLYSIS. J Biol Chem 239, 375–380 (1964).
 35. Zmuda-Trzebiatowska, E., Oknianska, A., Manganiello, V. & Degerman, E. Role of PDE3B in insulin-induced glucose uptake, 
GLUT-4 translocation and lipogenesis in primary rat adipocytes. Cell Signal 18, 382–390, https://doi.org/10.1016/j.
cellsig.2005.05.007 (2006).
 36. Edlund, A., Esguerra, J. L., Wendt, A., Flodström-Tullberg, M. & Eliasson, L. CFTR and Anoctamin 1 (ANO1) contribute to cAMP 
amplified exocytosis and insulin secretion in human and murine pancreatic beta-cells. BMC Med 12, 87, https://doi.
org/10.1186/1741-7015-12-87 (2014).
Acknowledgements
We thank professor emeritus C. Wollheim for critical reading of the manuscript, Esa Laurila (Lund University) for 
technical assistance, the Nordic Network for Clinical Islet Transplantation (Uppsala University, Sweden) and the 
Human Tissue Laboratory (Lund University, Sweden) for providing human islets of Langerhans. Support by the 
Swedish Research Council Linnaeus grant: Lund University Diabetes Centre (349-2006-237), SFO Exodiab (2009-
1039) and project grant to LE (2012–13146). Additional funding: European Research Council (ERC)—Advanced 
Researcher Grant (GA 269045), ALF, Royal Physiographic Society of Lund, Gyllenstierna Krapperup foundation, 
Ernhold Lundströms foundation, Filip Lundberg foundation, Crafoord foundation, Wallenberg foundation, 
Novo Nordisk foundation, Magnus Bergvall foundation, Påhlsson foundation, Diabetes Wellness, Swedish 
Diabetes Research Foundation (2009-060), The Swedish Diabetes Foundation, European Community’s Seventh 
Framework Program (FP7/2007–2013) and Ministerio de Economía y Competitividad of Spain (PI14/01509). 
AE is employed through a SRC-grant from the The Cystic Fibrosis trust (UK). The funders had no role in study 
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Contributions
K.S., L.G., J.A.L.C., H.C.H. and O.H. were responsible for the study design. K.S., D.M.A., F.O., A.E., L.H., S.W.J., 
M.M.R., C.E., A.P.L., O.E., I.P.S., M.M. and K.G.S. conducted experiments. K.S., D.M.A., F.O., P.A., Y.Z., P.P.V., 
N.O., E.A., N.W., L.E., A.V., K.G.S., C.F., J.A.L.C. and O.H. were responsible for acquiring and analyzing data. K.S. 
and O.H. wrote the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-21099-1.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
www.nature.com/scientificreports/
1 2SCIEntIFIC REpORtS |  (2018) 8:3016  | DOI:10.1038/s41598-018-21099-1
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
